Formulation Development
IsomAb Announces Strategic Collaboration With Catalent
IsomAb Ltd, a UK-based biotechnology company developing isoform-specific, disease-modifying antibody treatments for serious and life-threatening diseases, recently announced it has entered into a strategic collaboration…
Naobios & Sumagen Successfully Optimize HIV Vaccine Candidate for Industrial Production
Naobios and Sumagen Canada Inc. recently announced the production of the HIV-1 vaccine candidate at bench scale. This key milestone puts Naobios in a position…
VALANX Biotech & Fina Biosolutions Introduce ClickCRM for Rapid Conjugate Vaccine Development
VALANX Biotech and Fina Biosolutions LLC recently announced the signing of a joint IP and licensing agreement. The companies will launch ClickCRM, a ready-to-conjugate version…
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
Sagimet Biosciences Inc. recently announced the successful completion of end-of-Phase 2 interactions with the US FDA, supporting the advancement of denifanstat into Phase 3 in…
Ardena Expands Bioanalytical Services in Europe
Ardena recently announced a substantial expansion of its Bioanalytical Services in the Netherlands. This strategic investment includes establishing a brand new bioanalytical lab at Ardena’s…
Eledon Pharmaceuticals Announces Positive Initial Data From Subjects With Type 1 Diabetes Treated With Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation
Eledon Pharmaceuticals, Inc. recently announced positive data for the first three islet transplant recipients treated with an immunosuppression regimen that includes tegoprubart, the company’s investigational…
Shuttle Pharma Doses First Patients in Phase 2 Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma
Shuttle Pharmaceuticals Holdings, Inc. recently announced the first three patients in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma…
Modifi Biosciences Acquired by Merck
Modifi Biosciences, Inc., a leader in the development of direct DNA modification enabled cancer therapeutics, recently announced it has been acquired by Merck, known as…
ImmunoPrecise Advances Anti-Aging Research With Mayo Clinic Study, Poised to Tap Into $81-Billion Market With AI Technology
ImmunoPrecise Antibodies Ltd. recently announced its significant contribution to a groundbreaking study. The research, led by top scientists at the Mayo Clinic, was initially published…
Monte Rosa Therapeutics Announces Global License Agreement With Novartis to Advance T & B Cell-Modulating VAV1-Directed Molecular Glue Degraders
Monte Rosa Therapeutics, Inc. recently announced a global exclusive development and commercialization license agreement with Novartis to advance VAV1 MGDs, including MRT-6160. MRT-6160 is currently in…
Cellevate Demonstrates Successful Scale-Up of its Cellevat3d Nanofiber Microcarriers for Biomanufacturing at Testa Center
Cellevate recently announced the successful scale-up of its ground-breaking Cellevat3d nanofiber microcarriers funded by Vinnova/STUNS Life Science. The study was performed at Testa Center in…
ViaNautis Bio Signs Strategic Collaboration Agreement With Lilly to Develop Novel Products Delivering Genetic Medicines
ViaNautis Bio recently announced a collaboration with Eli Lilly and Company in which ViaNautis will receive an initial upfront payment from Lilly, with the short-term…
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates
Candel Therapeutics, Inc. recently announced three presentations at the 16th Annual International Oncolytic Virotherapy Conference (IOVC), taking place October 27-30, 2024, in Rotterdam, the Netherlands. The…
Biora Therapeutics Shares Progress on Smaller BioJet Clinical Device With Largest Payload of Any Ingestible Injectable
Biora Therapeutics, Inc. is sharing progress on its development of the BioJet Oral Delivery Platform, which is designed to replace injection with needle-free, oral delivery,…
Pluri Collaborates With Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors
Pluri Inc. recently announced the Israel Innovation Authority (IIA) will fund Pluri’s collaboration with the Bar-Ilan University Research and Development Company Ltd., (BIRAD), the commercial…
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement With University of Cincinnati to Study for Endometriosis Treatment
Lisata Therapeutics, Inc. recently announced it has entered into a sponsored research agreement with the University of Cincinnati to investigate Lisata’s novel cyclic peptide product…
First-Ever Long-Acting Injectable for Malaria Prevention Administered to Study Volunteers
Medicines for Malaria Venture (MMV) and Quotient Sciences have begun the first clinical trial for a long-acting injectable (LAI) preventive compound for malaria. The trial,…
Catalent Boston Adds to Oral Spray Drying Capacity & Capabilities to Support Late-Stage Clinical Trials & Commercialization
Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies, and flexible manufacturing, has completed a series of upgrades to its large-scale spray…
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell & NK Cell Engagers Antibody Platform
Purple Biotech Ltd. recently announced new data regarding its tri-specific antibody platform, CAPTN-3, which were presented at the 36th European Organization for Research and Treatment…
Ocuphire Pharma Announces Acquisition of Opus Genetics
Ocuphire Pharma, Inc. recently announced the all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs). The merger creates…
